Clinical performance of fecal syndecan 2/tissue factor pathway inhibitor 2 gene methylation assay in colorectal cancer screening
10.13406/j.cnki.cyxb.003786
- VernacularTitle:粪便SDC2/TFPI2基因甲基化检测在结直肠癌筛查中的临床性能研究
- Author:
Tiao ZHANG
1
;
Yutong HAO
;
Haiyan WEN
;
Qijun LIU
Author Information
1. 重庆国际旅行卫生保健中心/重庆海关口岸门诊部,重庆 401147
- Keywords:
syndecan 2;
tissue factor pathway inhibitor 2;
methylation;
colorectal cancer;
screening
- From:
Journal of Chongqing Medical University
2025;50(7):983-987
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical performance of fecal syndecan 2(SDC2)/tissue factor pathway inhibitor 2(TFPI2)gene methylation assay in prospective colorectal cancer screening.Methods:The individuals who underwent routine physical examina-tion were enrolled as subjects,and their fecal samples were collected and tested with fecal SDC2/TFPI2 gene methylation assay.In addition,enteroscopy was recommended for the subjects with positive results.Results:A total of 1215 subjects received fecal SDC2/TFPI2 gene methylation assay,among whom there were 708 male subjects and 507 female subjects,with a mean age of(44.7±13.9)years.Among all subjects,28 had positive test results,resulting in a positive rate of 2.30%,and among these 28 subjects,27(96.43%)underwent enteroscopy,among whom 16(59.26%)had abnormal findings.With enteroscopy and/or pathological examination as diag-nostic criteria,fecal SDC2/TFPI2 gene methylation assay had a positive predictive value of 7.41%for colorectal cancer,22.22%for progressive precancerous lesion,and 7.41%for non-progressive precancerous lesion.Conclusion:Fecal SDC2/TFPI2 gene methyla-tion assay shows good clinical performance in prospective colorectal cancer screening and thus provides a noninvasive method for the screening and auxiliary diagnosis of colorectal cancer.
